Changeflow GovPing Pharma & Drug Safety Novel PARP7 Inhibitor and Use Thereof
Routine Rule Added Final

Novel PARP7 Inhibitor and Use Thereof

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4378938A1 filed by Shanghai Qilu Pharmaceutical Research and Development Centre Ltd., covering a novel PARP7 inhibitor and its therapeutic use. The application was published on April 8, 2026 under IPC classification C07D 403/10 (A61P 35/00 for anticancer indications). The designated states cover all major European Patent Convention contracting states including DE, FR, GB, IT, ES, NL, BE, CH, and others.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO published application EP4378938A1 covers a novel PARP7 inhibitor compound developed by Shanghai Qilu Pharmaceutical Research and Development Centre Ltd., with inventors YAN Xiaoxia, HUANG Guanxin, JU Wei, and SUN Daqing. The application is classified under C07D 403/10 with anticancer indication (A61P 35/00), indicating potential oncology therapeutic applications.\n\nAffected parties include pharmaceutical companies engaged in PARP inhibitor research, oncology drug development programs, and potential licensees interested in the PARP7靶点 space. Patent applicants and researchers in the competitive landscape should review the published claims to assess potential freedom-to-operate implications or licensing opportunities. The publication represents a publicly available prior art reference for subsequent patent applications in the PARP inhibitor field.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL PARP7 INHIBITOR AND USE THEREOF

Publication EP4378938A1 Kind: A1 Apr 08, 2026

Applicants

Shanghai Qilu Pharmaceutical Research and
Development Centre Ltd.

Inventors

YAN, Xiaoxia, HUANG, Guanxin, JU, Wei, SUN, Daqing

IPC Classifications

C07D 403/10 20060101AFI20250224BHEP C07D 237/32 20060101ALI20250224BHEP A61K 31/501 20060101ALI20250224BHEP A61P 35/00 20060101ALI20250224BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
EP4378938A1
Docket
EP4378938

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Pharmaceutical research Therapeutic compound development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!